Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Sep;15(9):605-619.
doi: 10.1038/nrd.2016.109. Epub 2016 Jul 15.

Twenty Years On: The Impact of Fragments on Drug Discovery

Affiliations
Review

Twenty Years On: The Impact of Fragments on Drug Discovery

Daniel A Erlanson et al. Nat Rev Drug Discov. .

Abstract

After 20 years of sometimes quiet growth, fragment-based drug discovery (FBDD) has become mainstream. More than 30 drug candidates derived from fragments have entered the clinic, with two approved and several more in advanced trials. FBDD has been widely applied in both academia and industry, as evidenced by the large number of papers from universities, non-profit research institutions, biotechnology companies and pharmaceutical companies. Moreover, FBDD draws on a diverse range of disciplines, from biochemistry and biophysics to computational and medicinal chemistry. As the promise of FBDD strategies becomes increasingly realized, now is an opportune time to draw lessons and point the way to the future. This Review briefly discusses how to design fragment libraries, how to select screening techniques and how to make the most of information gleaned from them. It also shows how concepts from FBDD have permeated and enhanced drug discovery efforts.

Similar articles

See all similar articles

Cited by 99 articles

See all "Cited by" articles

References

    1. Proc Natl Acad Sci U S A. 2015 Dec 29;112(52):15910-5 - PubMed
    1. ChemMedChem. 2013 Dec;8(12):2057-69 - PubMed
    1. J Med Chem. 2010 Apr 8;53(7):2719-40 - PubMed
    1. J Am Chem Soc. 2003 Jun 25;125(25):7696-703 - PubMed
    1. Nat Med. 2013 Feb;19(2):202-8 - PubMed

LinkOut - more resources

Feedback